Industry – July 10, 2026
Aker BioMarine: grows sales but profits slip in mixed quarter
Aker BioMarine posted second-quarter 2026 revenue of USD 57.9 million, up 5% year-over-year, the company said in an Oslo Børs disclosure. Adjusted EBITDA fell 4% to USD 12.9 million.
Krill oil revenue rose 21% to USD 31.5 million, driven by volume growth and a higher share of capsulated oil.
Human Health Ingredients led performance, with revenue up 17% to USD 34.1 million. Adjusted EBITDA rose 14% to USD 15.9 million.
Lower production in Houston during the quarter weighed on QHP sales but stabilised by quarter-end, the company said. EBITDA margin came in below last year on higher sales and marketing spending.
Consumer Health Products fell 6% to USD 26.4 million. Lang revenue declined 4% on weaker sales through key US retail chains, while brand Epion continues a marketing repositioning that dented short-term revenue. Adjusted EBITDA was USD 1.1 million.
“Krill oil sales continued their strong momentum in the second quarter, with revenues up 21% year-over-year on solid volume growth,” said CEO Matts Johansen.
Commercial wins
The company secured a new Lysoveta supply contract worth USD 4 million in first-year revenue. It also won a new Superba account ranking among its largest customers.
Aker BioMarine expects continued year-over-year growth and improved profit in Human Health Ingredients. Consumer Health Products should return to modest growth.
The sale process for protein brand Understory continues, with advanced talks with one interested party.
The company engaged Jefferies and Houlihan Lokey earlier this year to explore interest in the Human Health Ingredient business. The mandate covers different alternatives and aims for a transaction in 2026.
Investors should watch progress on that process, and whether Consumer Health Products stabilises in the second half.
